The combination of the HDAC inhibitor panobinostat with the BET inhibitor I-BET151 showed synergistic caspase-dependent apoptosis induction in patient-derived BRAFV600E melanoma cells (patient-1-post, patient-3-post) with acquired vemurafenib resistance, but not in melanocytes [Table 2]. This evidence concerns the gene HDAC9 and melanoma.